Acceleron Pharma Inc. Stock News

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2021 Results - Earnings Call Transcript

Acceleron (XLRN) delivered earnings and revenue surprises of -14.13% and -10.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 208.82% over the past year to ($1.05), which

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second qua

With the trading day closing in on the halfway point, traders were feeling the heat as all the major indexes were ripping downward.

Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics t

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript

Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics

Acceleron's stock price is near a 52-week high. Reblozyl sales are growing rapidly.

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.